Sex differences in adverse events in Medicare individuals ≥ 66 years of age post glioblastoma treatment,Journal of Neuro-Oncology

当前位置： X-MOL 学术 › J Neurooncol. › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

Sex differences in adverse events in Medicare individuals ≥ 66 years of age post glioblastoma treatment
Journal of Neuro-Oncology ( IF 3.9 ) Pub Date : 2024-04-02 , DOI: 10.1007/s11060-024-04652-z
Mantas Dmukauskas , Gino Cioffi , Kristin A. Waite , Andrew E. Sloan , Corey Neff , Mackenzie Price , Quinn T. Ostrom , Jill S. Barnholtz-Sloan

Abstract

Purpose

Glioblastoma (GB) is the most common primary malignant brain tumor with the highest incidence occurring in older adults with a median age at diagnosis of 64 years old. While treatment often improves survival it brings toxicities and adverse events (AE). Here we identify sex differences in treatment patterns and AE in individuals ≥ 66 years at diagnosis with GB.

Methods

Using the SEER-Medicare dataset sex differences in adverse events were assessed using multivariable logistic regression performed to calculate the male/female odds ratio (M/F OR) and 95% confidence intervals [95% CI] of experiencing an AE adjusted for demographic variables and Elixhauser comorbidity score.

Results

Males with GB were more likely to receive standard of care (SOC; Surgery with concurrent radio-chemotherapy) [20%] compared to females [17%], whereas females were more likely to receive no treatment [26%] compared to males [21%].

Females with GB receiving SOC were more likely to develop gastrointestinal disorders (M/F OR = 0.76; 95% CI,0.64–0.91, p = 0.002) or blood and lymphatic system disorders (M/F OR = 0.79; 95% CI,0.66–0.95, p = 0.012). Males with GB receiving SOC were more likely to develop cardiac disorders (M/F OR = 1.21; 95% CI,1.02–1.44, p = 0.029) and renal disorders (M/F OR = 1.65; 95% CI,1.37–2.01, p < 0.001).

Conclusions

Sex differences for individuals, 66 years and older, diagnosed with GB exist in treatment received and adverse events developed across different treatment modalities.

中文翻译：

胶质母细胞瘤治疗后年龄≥ 66 岁的医疗保险个体不良事件的性别差异

摘要

目的

胶质母细胞瘤 (GB) 是最常见的原发性恶性脑肿瘤，发病率最高的是老年人，诊断时的中位年龄为 64 岁。虽然治疗通常可以提高生存率，但也会带来毒性和不良事件 (AE)。在这里，我们确定了诊断为 GB 时年龄≥ 66 岁的个体在治疗模式和 AE 方面的性别差异。

方法

使用 SEER-Medicare 数据集，使用多变量逻辑回归来评估不良事件中的性别差异，以计算男性/女性比值比 (M/F OR) 和针对人口变量调整的 AE 经历的 95% 置信区间 [95% CI]和 Elixhauser 合并症评分。

结果

与女性 [17%] 相比，患有 GB 的男性更有可能接受标准护理（SOC；手术同时放化疗）[20%]，而与男性相比，女性更有可能不接受治疗 [26%]。 21%]。

接受 SOC 治疗的 GB 女性更有可能出现胃肠道疾病（M/F OR = 0.76；95% CI，0.64–0.91，p = 0.002）或血液和淋巴系统疾病（M/F OR = 0.79；95% CI， 0.66–0.95，p = 0.012）。接受 SOC 治疗的 GB 男性更有可能出现心脏疾病（M/F OR = 1.21；95% CI，1.02–1.44，p = 0.029）和肾脏疾病（M/F OR = 1.65；95% CI，1.37–2.01），p < 0.001）。